TABLE 2.

Main Outcomes in a Trial Evaluating 3 RDAs of Daily Zinc Administration as Treatment for Acute Diarrhea in Children 6 to 35 Months of Age

VariableStudy Group
PlaceboZincVitamin A-ZincCaretaker-Zinc
Duration of supplementation (d)10.69.910.010.0
Percent of days with scheduled syrup administration98.297.697.195.8
Average daily zinc ingested by the infants (mg/kg/d)01.91.91.9
Average daily zinc ingested by other children (mg/kg/d)03.13.13.1
Mean plasma zinc (μmol/dL) change (SD)*−0.2 (2.1)3.7 (5.9)4.6 (8.0)2.7 (4.7)
Mean plasma copper (μmol/dL) change (SD)*−1.5 (4.2)−1.1 (5.5)−1.4 (4.1)−1.8 (4.5)
Relative hazard (time to recovery)11.26 (1.08, 1.46)1.21 (1.04, 1.38)1.19 (1.02, 1.40)
Risk Ratios or Ratios of Geometric Mean Compared With Placebo (95% CI)
Cases (%) with postenrollment duration >3 d159 (35.7)0.75 (0.61, 0.91)0.83 (0.68, 1.00)0.80 (0.66, 0.97)
Cases (%) with postenrollment duration >7 d58 (13.1)0.57 (0.38, 0.86)0.53 (0.35, 0.81)0.55 (0.37, 0.84)
Cases (%) with postenrollment duration >14 d11 (2.5)0.55 (0.20, 1.47)0.64 (0.25, 1.63)0.64 (0.25, 1.63)
Cases (%) with postenrollment watery diarrhea167 (37.6)0.91 (0.76, 1.08)0.90 (0.76, 1.08)1.03 (0.87, 1.21)
Geometric mean number of stools first 4 d (95% CI)13.9 (13.2, 14.6)0.91 (0.85, 0.97)0.95 (0.89, 1.02)0.93 (0.87, 1.00)
  • SD indicates standard deviation; CI, confidence interval.

  • * Change from enrollment until 14 days thereafter.